These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 2598189)

  • 21. Synergy of tumor necrosis factor and interleukin 2 in the activation of human cytotoxic lymphocytes: effect of tumor necrosis factor alpha and interleukin 2 in the generation of human lymphokine-activated killer cell cytotoxicity.
    Owen-Schaub LB; Gutterman JU; Grimm EA
    Cancer Res; 1988 Feb; 48(4):788-92. PubMed ID: 3257408
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reversal of suppression of lymphokine-activated killer cells by transforming growth factor-beta in ovarian carcinoma ascitic fluid requires interleukin-2 combined with anti-CD3 antibody.
    Hirte HW; Clark DA; O'Connell G; Rusthoven J; Mazurka J
    Cell Immunol; 1992 Jun; 142(1):207-16. PubMed ID: 1534038
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mechanisms of superior anti-tumor cytotoxic response of interleukin 15-induced lymphokine-activated killer cells.
    Ozdemir O; Ravindranath Y; Savaşan S
    J Immunother; 2005; 28(1):44-52. PubMed ID: 15614044
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human blood monocyte activation by Nocardia rubra cell wall skeleton for productions of interleukin 1 and tumor necrosis factor-alpha.
    Inamura N; Sone S; Ogawa T; Nishio M; Ogura T
    Biotherapy; 1992; 4(2):155-63. PubMed ID: 1622735
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TNF alpha enhancement of NK and LAK cell functions induced by high-dose IL-2 in human peripheral blood mononuclear cells from patients pretreated with alpha IFN + IL-2.
    Favrot M; Combaret V; Blay JY; Capdeville R; Zhou DC; Clapisson G; Chouaib S; Franks CR; Philip T
    Eur Cytokine Netw; 1990; 1(4):221-7. PubMed ID: 2104243
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cytotoxicity of interleukin 2-induced lymphokine-activated killer (LAK) cells against human leukemia and augmentation of killing by interferons and tumor necrosis factor.
    Teichmann JV; Ludwig WD; Thiel E
    Leuk Res; 1992; 16(3):287-98. PubMed ID: 1560676
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interleukin-12 synergizes with interleukin-2 to generate lymphokine-activated killer activity in peripheral blood mononuclear cells cultured in ovarian cancer ascitic fluid.
    Barton DP; Blanchard DK; Duan C; Roberts WS; Cavanagh D; DeCesare S; Djeu JY
    J Soc Gynecol Investig; 1995; 2(6):762-71. PubMed ID: 9420887
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transforming growth factor-beta 1 (TGF-beta 1) and recombinant human tumor necrosis factor-alpha reciprocally regulate the generation of lymphokine-activated killer cell activity. Comparison between natural porcine platelet-derived TGF-beta 1 and TGF-beta 2, and recombinant human TGF-beta 1.
    Espevik T; Figari IS; Ranges GE; Palladino MA
    J Immunol; 1988 Apr; 140(7):2312-6. PubMed ID: 3280680
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characteristics of interleukin-6-enhanced lymphokine-activated killer cell function.
    Iho S; Shau HY; Golub SH
    Cell Immunol; 1991 Jun; 135(1):66-77. PubMed ID: 2018984
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunomodulatory effects of systemic low-dose recombinant interleukin-2 and lymphokine-activated killer cells in humans.
    Eberlein TJ; Rodrick ML; Massaro AF; Jung SE; Mannick JA; Schoof DD
    Cancer Immunol Immunother; 1989; 30(3):145-50. PubMed ID: 2598183
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of OKT3-initiated lymphokine-activated effectors expanded with interleukin 2 and tumor necrosis factor alpha.
    Yang SC; Owen-Schaub LB; Roth JA; Grimm EA
    Cancer Res; 1990 Jun; 50(12):3526-32. PubMed ID: 2160321
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of tumour necrosis factor-alpha (TNF-alpha), IL-1 beta and monocytes on lymphokine-activated killer (LAK) induction from natural killer (NK) cells and T lymphocytes.
    Yoneda K; Osaki T; Yamamoto T; Ueta E
    Clin Exp Immunol; 1993 Aug; 93(2):229-36. PubMed ID: 8348749
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Functional interactions between interleukin-4, interleukin-2, and tumor necrosis factor-alpha for lymphokine-activated killer cell generation.
    Blay JY; Branellec D; Robinet E; Gay F; Chouaib S
    J Clin Lab Anal; 1990; 4(1):54-8. PubMed ID: 2313467
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of lethal irradiation and cyclosporin A treatment on the growth and tumoricidal activity of a T cell clone potentially useful in cancer therapy.
    Cesano A; Visonneau S; Cioé L; Clark SC; Santoli D
    Cancer Immunol Immunother; 1995 Mar; 40(3):139-51. PubMed ID: 7728772
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phenotypic and functional analysis of lymphokine-activated killer (LAK) cell clones. Ability of CD3+, LAK cell clones to produce interferon-gamma and tumor necrosis factor upon stimulation with tumor targets.
    Chong AS; Aleksijevic A; Scuderi P; Hersh EM; Grimes WJ
    Cancer Immunol Immunother; 1989; 29(4):270-8. PubMed ID: 2502310
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The liposome-incorporating cell wall skeleton of Mycobacterium bovis bacillus Calmette-Guéin can directly enhance the susceptibility of cancer cells to lymphokine-activated killer cells through up-regulation of natural-killer group 2, member D ligands.
    Miyazaki J; Kawai K; Kojima T; Oikawa T; Joraku A; Shimazui T; Nakaya A; Yano I; Nakamura T; Harashima H; Akaza H
    BJU Int; 2011 Nov; 108(9):1520-6. PubMed ID: 21314815
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Regulation of human cytolytic lymphocyte responses by interleukin-12.
    Gately MK; Wolitzky AG; Quinn PM; Chizzonite R
    Cell Immunol; 1992 Aug; 143(1):127-42. PubMed ID: 1352483
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.
    Gemlo BT; Palladino MA; Jaffe HS; Espevik TP; Rayner AA
    Cancer Res; 1988 Oct; 48(20):5864-7. PubMed ID: 3139285
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of various cytokines on the induction of lymphokine-activated killer cells.
    Bergmann L; Weidmann E; Bungert B; Hechler P; Mitrou PS
    Nat Immun Cell Growth Regul; 1990; 9(4):265-73. PubMed ID: 2120581
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ICAM-1 and LFA-3 enhance the ability of anti-CD3 mAb to stimulate interferon gamma production in interleukin-2-activated T cells.
    Chong AS; Jiang XL; Scuderi P; Lamas M; Graf LH
    Cancer Immunol Immunother; 1994 Aug; 39(2):127-34. PubMed ID: 7519126
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.